Mayo Clinic Center for clinical and Translational Science (CCaTS)

梅奥诊所临床和转化科学中心 (CCaTS)

基本信息

  • 批准号:
    10206302
  • 负责人:
  • 金额:
    $ 524.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-18 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

Contact PD/PI: Khosla, Sundeep Clinical and Translational Science (CTS) has been a fundamental and highly valued element of Mayo Clinic since its founding, and Mayo Clinic's mission “to provide the best care to every patient every day through integrated clinical practice, education, and research” has always aligned well with the NCATS mission. Mayo Clinic is an integrated academic group practice with major sites in Minnesota, Arizona, and Florida; a large community Health System (MCHS) in Minnesota, Wisconsin, and Iowa; and an affiliated national “Care Network” (MCCN). Thus, the Mayo Clinic Center for Clinical and Translational Science (CCaTS) is of national scope. MCHS and MCCN provide unique laboratories for late-stage dissemination and implementation research as well as for the conduct of high-priority clinical trials in community health care organizations. Mayo Clinic is also leading both a PCORI CDRN and a PPRN. These widespread connections, and programs that span the translational spectrum, position Mayo Clinic CCaTS to become a true “hub” for CTS. The present application builds on key accomplishments over the previous 5 years in each of the major areas relevant to the NCATS mission. Mayo CCaTS has mature, innovative programs in workforce development for all members of CTS teams and is diversifying them through online and experiential learning. Incentivizing Team Science has always been part of the institutional culture at Mayo, and we are continuing to build on that strength. Given its role, particularly in Rochester, as a major local and regional provider of health care, community engagement has also been a priority for Mayo Clinic, and a range of methods for bidirectional engagement are proposed. Advances in informatics are also enabling us to connect with new and diverse patient populations. Thus, in light of our institutional traditions and accomplishments over the past 5 years, we believe we are uniquely positioned to accomplish our Specific Aims: Aim 1. Train and maintain an outstanding multidisciplinary CTS workforce, including the entire spectrum of individuals involved in CTS; Aim 2. Eliminate barriers to the work of translation by streamlining methods and processes, including improved and innovative informatics tools, completing the transformation of Mayo's clinical trial process, and accelerating the implementation of trial results and other discoveries to improve patient care; Aim 3. Engage and incorporate a range of diverse stakeholders as active participants in CCaTS, both in leadership roles and in specific research projects, to improve the process of translation and the delivery of health care, promoting community engagement in research among our Mayo workforce and engaging our local and national communities using both traditional and innovative approaches; and Aim 4. Expand, strengthen, and streamline our regional and national collaborations in all aspects of CTS and education, connecting with our regional and national partners, as well as with the CTSA Consortium, to achieve the ultimate goal of NCATS to improve patient care and human health.
联系PD/PI: Khosla, Sundeep

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Claudia F. Lucchinetti其他文献

Engaging and Empowering the Front Lines During the COVID-19 Outpatient Practice Reactivation
  • DOI:
    10.1016/j.mayocp.2020.06.040
  • 发表时间:
    2020-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Claudia F. Lucchinetti;Alexander G. von Bormann;Jill J. Nagel;Amie E. Jones;John C. O’Horo;Matthew R. Callstrom;Kimberly K. Amrami;Jean E. Barth;Laura E. Breeher;Matthew R. Callstrom;Sean C. Dowdy;Theresa S. Evers;Dawn L. Hucke;Ryan T. Hurt;Amie E. Jones;Claudia F. Lucchinetti;Jill J. Nagel;John C. O’Horo;Kimberly K. Otte;Rachel L. Pringnitz
  • 通讯作者:
    Rachel L. Pringnitz
MOG antibody-associated disease epidemiology in Olmsted County, USA, and Martinique
  • DOI:
    10.1007/s00415-024-12861-9
  • 发表时间:
    2025-01-15
  • 期刊:
  • 影响因子:
    4.600
  • 作者:
    Laura Cacciaguerra;Elia Sechi;Isabelle Komla-Soukha;John J. Chen;Carin Y. Smith;Sarah M. Jenkins;Kai Guo;Vyanka Redenbaugh;James P. Fryer;Jan-Mendelt Tillema;Nisa Vorasoot;Nanthaya Tisavipat;Smathorn Thakolwiboon;Divyanshu Dubey;Anastasia Zekeridou;Andrew McKeon;W. Oliver Tobin;Orhun H. Kantarci;B. Mark Keegan;Deena A. Tajfirouz;Kevin D. Chodnicki;Jay Mandrekar;Claudia F. Lucchinetti;Sebastian A. Lopez-Chiriboga;Nabeela Nathoo;Nycole K. Joseph;Michelle F. Devine;Jessica A. Sagen;Sean J. Pittock;Philippe Cabre;Eoin P. Flanagan
  • 通讯作者:
    Eoin P. Flanagan

Claudia F. Lucchinetti的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Claudia F. Lucchinetti', 18)}}的其他基金

Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Regan Theiler)
梅奥诊所临床和转化科学中心(CCaTS UL1 补充 - Regan Theiler 博士)
  • 批准号:
    10195445
  • 财政年份:
    2017
  • 资助金额:
    $ 524.35万
  • 项目类别:
Mayo Clinic Center for clinical and Translational Science (CCaTS)
梅奥诊所临床和转化科学中心 (CCaTS)
  • 批准号:
    9981496
  • 财政年份:
    2017
  • 资助金额:
    $ 524.35万
  • 项目类别:
Genetic Determinants of Pathologic Heterogeneity in MS
MS 病理异质性的遗传决定因素
  • 批准号:
    7099742
  • 财政年份:
    2006
  • 资助金额:
    $ 524.35万
  • 项目类别:
Mechanisms of Multiple Sclerosis Tissue Pathology
多发性硬化症组织病理学机制
  • 批准号:
    8259696
  • 财政年份:
    2006
  • 资助金额:
    $ 524.35万
  • 项目类别:
Mechanisms of Multiple Sclerosis Tissue Pathology
多发性硬化症组织病理学机制
  • 批准号:
    8065972
  • 财政年份:
    2006
  • 资助金额:
    $ 524.35万
  • 项目类别:
Mechanisms of Multiple Sclerosis Tissue Pathology
多发性硬化症组织病理学机制
  • 批准号:
    7883294
  • 财政年份:
    2006
  • 资助金额:
    $ 524.35万
  • 项目类别:
Genetic Determinants of Pathologic Heterogeneity in MS
MS 病理异质性的遗传决定因素
  • 批准号:
    7232273
  • 财政年份:
    2006
  • 资助金额:
    $ 524.35万
  • 项目类别:
Genetic Determinants of Pathologic Heterogeneity in MS
MS 病理异质性的遗传决定因素
  • 批准号:
    7418624
  • 财政年份:
    2006
  • 资助金额:
    $ 524.35万
  • 项目类别:
THE CLINICO-PATHOLOGICAL CORRELATES OF THE MULTIPLE SCLEROSIS LESION
多发性硬化症病变的临床病理相关性
  • 批准号:
    7206081
  • 财政年份:
    2005
  • 资助金额:
    $ 524.35万
  • 项目类别:
The Clinico-Pathological Correlates of the MS Lesion
MS 病变的临床病理相关性
  • 批准号:
    7042277
  • 财政年份:
    2003
  • 资助金额:
    $ 524.35万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 524.35万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了